On Nov. 21, Dr. Yu Qiang, the founder of CGeneTech and the president of SIP Talent Innovation and Entrepreneurship Promotion Association, successfully held the fourth stop of enterprise visit, which was guided by the Organization Department of SIP Industrial Committee, sponsored by SIP Enterprise Development Service Center and organized by SIP Talent Innovation and Entrepreneurship Promotion Association, and exchanged the "sweet and sour" of innovative drug field with more than 10 entrepreneurs and managers on site.

　　CGeneTech, which took root in Suzhou Industrial Park in 2010, is a biotech company dedicated to small molecule drug development in the fields of hypoglycemia, antitumor and rare diseases. At present, it has 6 clinical approvals and has applied for 30 invention patents. More than half of the 14 granted invention patents are global oriented, and Centec is on its way to the world based in China.

　　Since its inception, the company has built a rich pipeline of Class 1 innovative drugs, including the self-developed Shengliptin phosphate, a novel DPP-4 inhibitor, which is in Phase III clinical stage and is expected to complete Phase III clinical in mid-2022. This is just like the image metaphor often used by Dr. Yu Qiang, "Without climbing over snowy mountains and wading through grasslands, it is impossible to liberate the whole China". This is a sign that the first innovative drug of Shengshi Tai Ke will go to market for approval next year and reach the clinical efficacy endpoint. The approval of Shenggliptin phosphate will fill the gap of DPP-4 inhibitors in China (all the approved ones are imported for registration) and has a broad market prospect. When Dr. Yu Qiang modestly described this milestone as "the first step of a long march", the whole audience spontaneously applauded warmly, and colleagues in the industry deeply understood how much perseverance and hard work was behind this weighty phrase.

　　"The deadline of our project is always yesterday!" This "mantra" of CGeneTech shows the strict requirements of their project management, and the company has developed to a high level of talent stability, with no one above the director level jumping ship, which is rare in the background of the era of serious talent in-roll, and also reflects the cultural charm and endogenous power of this company from the side.

　　In the subsequent exchange, the participants had a lively discussion on industry trends, business models, innovation to the sea and other topics. Kui-Feng Wang, CEO of Qinhao Pharmaceuticals, Gao-Xi Jiang, CEO of Weinz Bio, and colleagues from Sequence Health Medical and Sensitive Microsystems threw out their insights and questions to deepen the links and expand the cooperation space in the exchange.

　(by "Suzhou Industrial Park Smart Talent")